CIK 0001177648 · Non-accelerated filer<br>Smaller reporting company
ENANTA PHARMACEUTICALS INC
Sign in to watch- Ticker
- ENTA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Sep 30
- Entity type
- operating
- EIN
- 043205099
- Phone
- 617 607 0800
- Business address
- 4 KINGSBURY AVENUE, WATERTOWN, MA, 02472
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-08-08 | Rottinghaus Scott T. Chief Medical Officer | Shares withheld for taxes | −1,467 | $13.34 | $20K | 23,787 |
| 2026-03-11 | Vance Terry Director | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2026-03-11 | Russell Lesley Director | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2026-03-11 | Peterson Kristine Director | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2026-03-11 | Hata Yujiro S Director | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2026-03-11 | FOLETTA MARK G Director | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2026-03-11 | CARTER BRUCE L A Director | Grant or award · Stock Option (right to buy) | +20,000 | 20,000 | ||
| 2026-02-12 | Kowalsky Matthew Paul Chief Legal Officer | Grant or award | +1,318 | 1,318 | ||
| 2026-02-12 | Kowalsky Matthew Paul Chief Legal Officer | Grant or award | +4,175 | 5,493 | ||
| 2026-02-12 | Kowalsky Matthew Paul Chief Legal Officer | Shares withheld for taxes | −1,902 | $14.25 | $27K | 3,591 |
| 2026-02-12 | Luu Brendan Chief Business Officer | Grant or award | +1,575 | 39,904 | ||
| 2026-02-12 | Luu Brendan Chief Business Officer | Grant or award | +4,987 | 44,891 | ||
| 2026-02-12 | Luu Brendan Chief Business Officer | Shares withheld for taxes | −3,257 | $14.25 | $46K | 41,634 |
| 2026-02-12 | Kieffer Tara Lynn Chief Product Strategy Officer | Grant or award | +1,575 | 32,195 | ||
| 2026-02-12 | Kieffer Tara Lynn Chief Product Strategy Officer | Grant or award | +4,987 | 37,182 | ||
| 2026-02-12 | Kieffer Tara Lynn Chief Product Strategy Officer | Shares withheld for taxes | −3,257 | $14.25 | $46K | 33,925 |
| 2026-02-12 | Rottinghaus Scott T. Chief Medical Officer | Grant or award | +1,650 | 23,442 | ||
| 2026-02-12 | Rottinghaus Scott T. Chief Medical Officer | Grant or award | +5,225 | 28,667 | ||
| 2026-02-12 | Rottinghaus Scott T. Chief Medical Officer | Shares withheld for taxes | −3,413 | $14.25 | $49K | 25,254 |
| 2026-02-12 | Or Yat Sun Chief Scientific Officer | Grant or award | +1,650 | 373,042 |
Page 1 of 7 · 135 trades